151 related articles for article (PubMed ID: 29577356)
1. Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
Babcook MA; Akgul M; Margevicius S; MacLennan GT; Fu P; Abouassaly R; Gupta S
Prostate; 2018 Jul; 78(10):714-723. PubMed ID: 29577356
[TBL] [Abstract][Full Text] [Related]
2. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.
Babcook MA; Shukla S; Fu P; Vazquez EJ; Puchowicz MA; Molter JP; Oak CZ; MacLennan GT; Flask CA; Lindner DJ; Parker Y; Daneshgari F; Gupta S
Mol Cancer Ther; 2014 Oct; 13(10):2288-302. PubMed ID: 25122066
[TBL] [Abstract][Full Text] [Related]
3. SIRT1, AMP-activated protein kinase phosphorylation and downstream kinases in response to a single bout of sprint exercise: influence of glucose ingestion.
Guerra B; Guadalupe-Grau A; Fuentes T; Ponce-González JG; Morales-Alamo D; Olmedillas H; Guillén-Salgado J; Santana A; Calbet JA
Eur J Appl Physiol; 2010 Jul; 109(4):731-43. PubMed ID: 20217115
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
5. Critical role for free radicals on sprint exercise-induced CaMKII and AMPKα phosphorylation in human skeletal muscle.
Morales-Alamo D; Ponce-González JG; Guadalupe-Grau A; Rodríguez-García L; Santana A; Cusso R; Guerrero M; Dorado C; Guerra B; Calbet JA
J Appl Physiol (1985); 2013 Mar; 114(5):566-77. PubMed ID: 23288553
[TBL] [Abstract][Full Text] [Related]
6. Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells.
Xiang S; Zhang Q; Tang Q; Zheng F; Wu J; Yang L; Hann SS
Sci Rep; 2016 Nov; 6():36721. PubMed ID: 27830724
[TBL] [Abstract][Full Text] [Related]
7. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
8. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
9. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
10. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
12. Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK-Mediated Phosphorylation of Akt.
Wang N; Yao M; Xu J; Quan Y; Zhang K; Yang R; Gao WQ
Clin Cancer Res; 2015 Oct; 21(20):4676-85. PubMed ID: 26071486
[TBL] [Abstract][Full Text] [Related]
13. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
14. True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Böker A; Kuczyk MA; Kramer MW; Merseburger AS; Krüger K; Imkamp F; von Klot CA
Adv Ther; 2017 Jan; 34(1):171-179. PubMed ID: 27889882
[TBL] [Abstract][Full Text] [Related]
15. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
16. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
18. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
19. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians.
Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A
Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280
[TBL] [Abstract][Full Text] [Related]
20. Leptin-stimulated endothelial nitric-oxide synthase via an adenosine 5'-monophosphate-activated protein kinase/Akt signaling pathway is attenuated by interaction with C-reactive protein.
Procopio C; Andreozzi F; Laratta E; Cassese A; Beguinot F; Arturi F; Hribal ML; Perticone F; Sesti G
Endocrinology; 2009 Aug; 150(8):3584-93. PubMed ID: 19359389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
